SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Innovative Cannabinoid Drug Shows Promise for Alzheimer's Patients
- Spectral AI Lowers Warrant Prices for Enhanced Investment Appeal
- Alector Faces Setbacks as Alzheimer’s Drug Falls Short in Trials
- Perplexity and Quartr API Collaboration Enhances Retail Insights
- Analyzing Rockwell Automation's Short Interest Trends and Insights
- Understanding Market Sentiment Surrounding Exicure Stock
- Exploring Kirby's Short Interest Dynamics and Implications
- Poland's Firm Stance Against EU-Mercosur Trade Agreement
- SOWG Stock Faces Challenges While Showing Revenue Resilience
- Post Holdings (NYSE: POST) Stocks Hit Record High Amid Growth
- Investigation of Corporate Mergers: Insights for Shareholders
- Dye & Durham Communicates Key Updates Ahead of Shareholder Meeting
- LuxUrban Hotels Stock Hits New Low: Financial Struggles Ahead
- Nordstrom's Path Ahead: Analyzing Q3 Earnings Insights
- Subway's Transition: Carrie Walsh Steps Up as Interim CEO
- Expanding Medicare Coverage: A Game-Changer for Obesity Treatments
- Eli Lilly and Amazon Shine Bright in Stock Market Movements
- Three Reasons to Embrace the Bull Market Ahead in 2025
- Exploring Cava Group's Bearish Options Trends and Market Dynamics
- Celsius Holdings: Insights on Recent Options Trading Developments
- Archer Aviation's Bullish Options Activity Sparks Interest
- Builders Struggle Amid Lower Housing Starts and Rising Rates
- Understanding CVS Health's Recent Insider Trading Activity
- CVS Health Insider Buy Signals Stock Confidence from Leadership
- Jeffrey R Balser’s Significant Investment in CVS Health Stock
- Exploring CVS Health Stock: Insights and Future Prospects
- Insider Purchase Signals Confidence in Shoals Technologies Stock
- Kishore Korde's Strategic Move: Insights on Air Lease Stock
- Cheryl Norton Offloads American Water Works Shares Worth $642K
- Douglas R Casella Sells $2.25M Stake in Waste Management
- Michael K Burke Exits His Position in Casella Waste Systems
- Kenneth Bacon's Strategic Move: Selling Comcast Shares
- Stratus Properties Insider Transaction Highlights Recent Trends
- Daniel Fuller Makes Bold Move: Signals Shift at Brinker International
- Insightful Developments at Criteo: Insider Activity Analyzed
- Joan Lordi Amble's Strategic $294K Investment in BAH Shares
- Catherine A Kehr Sells $4.34 Million in Expand Energy Stock
- What Investors Should Expect from Arbe Robotics Earnings
- VinFast Achieves Major Growth in Q3 2024 Financial Results
- Abercrombie & Fitch Reports Strong Q3 Performance with Growth
- Morocco's Stock Market Shows Positive Trends Amid Market Fluctuations
- Consumer Sentiment Soars as Optimism About Labor Market Grows
- Redwire Corporation Experiences Stellar Stock Growth
- InfiniT Acquisition Corp. Stock Plummets to New Low of $1.68
- Vigil Neuroscience Faces Challenges Amid 52-Week Low in Stocks
- Quartet Merger Corp. Faces 52-Week Low Amid Market Trends
- Borr Drilling Faces Market Struggles Amid 52-Week Low
- Leslie's Stock Faces Challenges, Yet Shows Signs of Recovery
- Economic Forecasts Predict Turbulent Financial Landscape Ahead
- Solana Price Update: Navigating Recent Market Challenges